Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 12/2011

01-12-2011 | Research Articles

Transthoracic oesophagectomy with lymphadenectomy in 100 oesophageal cancer patients. Multidisciplinary approach

Authors: Víctor Valentí, José Luis Hernández-Lizoain, Fernando Martínez-Regueira, Manuel Bellver, Javier Rodríguez, Juan Antonio Díaz González, Wenceslao Torres, Jesus Javier Sola, Javier Álvarez-Cienfuegos

Published in: Clinical and Translational Oncology | Issue 12/2011

Login to get access
Metadata
Title
Transthoracic oesophagectomy with lymphadenectomy in 100 oesophageal cancer patients. Multidisciplinary approach
Authors
Víctor Valentí
José Luis Hernández-Lizoain
Fernando Martínez-Regueira
Manuel Bellver
Javier Rodríguez
Juan Antonio Díaz González
Wenceslao Torres
Jesus Javier Sola
Javier Álvarez-Cienfuegos
Publication date
01-12-2011
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 12/2011
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-011-0752-4

Other articles of this Issue 12/2011

Clinical and Translational Oncology 12/2011 Go to the issue

Special Article

Recommendations and expert opinion on the treatment of locally advanced rectal cancer in Spain

Research Articles

Does overall treatment time impact on survival after whole-brain radiotherapy for brain metastases?

Research Articles

Cost-effectiveness evaluation of sunitinib as first-line targeted therapy for metastatic renal cell carcinoma in Spain

Research Articles

FP3: a novel VEGF blocker with antiangiogenic effects in vitro and antitumour effects in vivo

Educational Series / Green Series

The therapeutic potential of TRAIL receptor signalling in cancer cells

Educational Series / Red Series

Real-time intravital imaging of cancer models
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits